LifeShield™ Neutron™ Catheter Patency Device

It’s Time to Stop Blood Reflux from Complicating IV Therapy

Neutron Product Photo 248x150Blood reflux into either the IV catheter or the needleless connector is the primary cause of partial and complete occlusions.1 The reflux of blood may increase both the risk of occlusion and biofilm formation, which may lead to an infection. Occlusions occur in up to 25% of all central venous catheters (CVCs) placed annually in the US.2,3 A partial or complete occlusion can limit or prevent the ability to withdraw blood, flush the catheter, and/or administer parenteral solutions or medications.4

Occlusions may lead to:
  • Delays in therapy5
  • Discomfort caused by corrective steps necessary to restore catheter patency1,6
  • Risks associated with the use of declotting agents such as tissue plasminogen activator (t-PA)7,8
  • Flushing of the line, which could release part of a thrombus into the bloodstream6,9
  • The need of heparin (hep lock) in flush and lock solutions10

The LifeShield Neutron catheter patency device is an innovative device designed to maintain constant neutral pressure and helps reduce blood reflux11,12

The LifeShield Neutron’s unique features include:

new_Neutron Middle Image

Help enhance care and optimize patient safety with the LifeShield Neutron from Hospira. For more information, contact your Hospira sales representative or call us at 1-877-946-7747.

  1. Data on file, Hospira, Inc. Keeping the lines open with evidence-based practice and advanced technologies. Schallom L. 2008.
  2. Stephens LC, Haire WD, Kotulak GD. Are clinical signs accurate indicators of the cause of central venous catheter occlusion? Journal of Parenteral and Enteral Nutrition. 1995;19(1):75-79.
  3. Jacobs BR, Schilling S, Doellman D, et al. Central venous catheter occlusion: A prospective, controlled trial examining the impact of a positive-pressure valve device. Journal of Parenteral and Enteral Nutrition. 2004;28(2):113-118.
  4. Gorski L. Central venous access device occlusions: Part 1: Thrombotic causes and treatment. Home Healthc Nurse. 2003;21(2)115-121.
  5. Wingerter L. Vascular access device thrombosis. Clin J Oncol Nurs. 2003;7(3):345-348.
  6. Hadaway LC. Reopen the pipeline for I.V. therapy. Nursing. 2005;35(8):54-61.
  7. Kerner JA, Garcia-Careaga MG, Fisher AA, Poole RL. Treatment of catheter occlusion in pediatric patients. J Parenter Enteral Nutr. 2006;30(1 suppl.):S73-S81
  8. Activase [package insert]. San Francisco, CA: Genentech, Inc.; 2011.
  9. Macklin D. Catheter management. Semin Oncol Nurs. 2010;26(2):113-120.
  10. Boersma RS, Jie KSG, Verbon A, van Pampus ECM, Schouten HC. Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. Ann Oncol. 2008;19(3):433-442.
  11. Data on file, ICU Medical, Inc. Neutron 510(k).
  12. Data on file. ICU Medical, Inc. MI-1307.
  13. Guidelines for the prevention of intravascular catheter-related bloodstream infections, 2011. Centers for Disease Control and Prevention Web site. www.cdc.gov/hicpac/BSI/BSI-guidelines-2011.html. Accessed September 19, 2012.
  14. Bouza E, Muñoz P, López-Rodríguez J, et al. A needleless closed system device (CLAVE) protects from intravascular catheter tip and hub colonization: a prospective randomized study. J Hosp Infect. 2003;54(4):279-287.